New Digital Pathology Vendor – Welcome to DigiPath, Inc.
A new digital pathology vendor hits the market today. Affordable and innovative solutions to meet both clinical and research/biopharma needs will be required for DigiPath in an increasingly competitive landscape, particularly for hospitals – both community-based groups and academic medical centers to be successful. Check out their new website at www.digipath.biz for more information.
DigiPath, Inc.™ today announced its entry into the digital pathology market. DigiPath provides the next generation of affordable, innovative, and reliable digital pathology solutions. DigiPath’s solutions will support community pathology practices, hospitals, academic medical centers, reference laboratories, biopharma organizations, and life science research institutions.
“The medical community is looking for more affordable, innovative, and reliable digital pathology solutions to assist in enhancing patient care,” commented Keith Kaplan, M.D., Editor, Digital Pathology Blog™ at www.tissuepathology.com. “DigiPath seems well positioned to help our community practices expand digital pathology adoption.”
“In June 2010, we surveyed over 400 CLIA™ certified labs concerning digital pathology adoption”, stated Jondavid Klipp, Publisher, Laboratory Economics™. “55% of the respondents said that digital pathology was too expensive. Affordability is an important concern to pathology laboratories.”
“The DigiPath team brings a combined 60 year experience within the digital pathology field”, said Eric Stoppenhagen, Chief Executive Officer. “Our team pioneered digital pathology by implementing over 500 installations worldwide. During the coming years, DigiPath will be providing affordable, innovative, and reliable digital pathology solutions.”
About DigiPath, Inc.
DigiPath, Inc. provides the next generation of affordable, innovative, and reliable digital pathology solutions. DigiPath’s advisors bring over 60 years combined expertise in pioneering digital pathology, implementing over 500 installations at community pathology practices, hospitals, academic medical centers, reference laboratories, biopharma organizations, and life science research institutions worldwide.
Visit www.digipath.biz monthly to see new solutions emerge during 2011.
SAFE HARBOR STATEMENT
This Press Release may contain certain forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. DigiPath has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates," "believes," "estimates," "expects," "plans," "intends," "potential" and similar expressions. These statements reflect DigiPath's current beliefs and are based upon information currently available to it. Accordingly, such forward-looking statements involve known and unknown risks, uncertainties and other factors which could cause DigiPath's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. DigiPath undertakes no obligation to update or provide advice in the event of any change, addition or alteration to the information catered in this Press Release including such forward-looking statements.
